Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of BI 655066 in Crohn's disease
2015-001834-15Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of risankizumab in Crohn's disease, sponsored by Boehringer Ingelheim. Primary endpoint: Incidence of drug-related adverse events. Started Jun 2015; status: completed.
02
Drugs
risankizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2015-001834-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001834-15.